Radiopharm Theranostics maintains a "Hold" rating as its radiotherapeutic pipeline advances, with key data readouts expected in 2026. Click here to read.
A novel immunotherapy combination is proving to be both safe and manageable for patients with prostate cancer, according to updated Phase 1 trial data presented at the 2026 ASCO Genitourinary Cancers ...
Partnership links high-performance motorsports with nuclear energy innovation and life-saving medical isotopes. ARLINGTON, Texas, March 11, 2026 /PRNewswire/ -- HVM Racing and its Nuclear Clean Air ...
Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver ...
Dosimetry data from the Phase 3 ECLIPSE substudy demonstrated favorable organ radiation absorbed doses supporting administration of 7.4 GBq for up to six cycles ...
Stockhead on MSN
Health Check: Telix jumps first hurdle with its advanced prostate cancer therapy trial
In welcome good news, Telix says the first stage of its pivotal prostate cancer therapeutic trial has hit its desired safety ...
Webcast and conference call to be held today, Tuesday March 10 at 9:30 a.m. AEDT (Monday March 9 at 6:30 p.m. EDT). Investors can register at the ...
TLX591-Tx (lutetium-177 rosopatamab tetraxetan) is an investigational PSMA-targeted radio antibody-drug conjugate (rADC) for metastatic castration-resistant prostate cancer (mCRPC). The ProstACT ...
Australian radiopharma developer Telix Pharmaceuticals has announces that Part 1 of the ProstACT Global Phase III study, the safety and dosimetry lead-in for its therapeutic candidate – TLX591-Tx ...
Actinium-225 is a targeted and highly-potent alpha emitter that holds promise for patients who do not respond to lutetium-177 therapy. Rahul Parikh, MD, PhD, of University of Kansas, shared his ...
Telix reported FY2025 revenue of $804M, up 56% YoY, with Precision Portfolio products Illuccix and Gozellix contributing $622M. Read why TLX stock is a Buy.
A new analysis of the chemical make-up of meteorites has helped scientists work out when the Earth formed its layers.The research by an international team of scientists confirmed the Earth's first ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results